Arbutus Biopharma
ABUS
ABUS
112 hedge funds and large institutions have $119M invested in Arbutus Biopharma in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 40 increasing their positions, 37 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
112
Holders Change
-6
Holders Change %
-5.08%
% of All Funds
1.89%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
40
Reduced
37
Closed
19
Calls
$4.81M
Puts
$2.63M
Net Calls
+$2.18M
Net Calls Change
+$3.47M
Top Buyers
| 1 |
1
Millennium Management
New York
|
$11.3M |
| 2 |
TSC
2
Two Seas Capital
Rye,
New York
|
$9.49M |
| 3 |
3
BlackRock
New York
|
$20.4M |
| 4 |
4
Vanguard Group
Malvern,
Pennsylvania
|
$14.1M |
| 5 |
FCM
5
FourWorld Capital Management
New York
|
$4.88M |
